Institutional Conflict of Interest Management and Monitoring Plan: RadioPharm Ventures

The University of Texas MD Anderson (MD Anderson) and RadioPharm Ventures (RV) are parties to a Technology Commercialization Agreement (Agreement). The Agreement will comprise of targets identified by MD Anderson using state-of-the art mass-spectrometry proteomic techniques. RadioPharm Ventures was created as a joint venture between MD Anderson and Radiopharm Theranostics Ltd.

Under the Agreement, MD Anderson will receive equity and royalty and milestone payments for the contribution of both existing intellectual property and of future intellectual property that will be created under Sponsored Research Agreements (collectively, Licensed Technology). Under the MD Anderson Intellectual Property Policy, # ADM0345, David Piwnica-Worms and the other co-creators of the Licensed Technology are entitled to 50% of the license income from the Agreements.

Dr. David Piwnica-Worms, Department Chair of Cancer Systems Imaging, is an Institutional Decision Maker under the Institutional Conflict of Interest Policy for MD Anderson and its Institutional Decision Makers (IDM), MD Anderson Institutional Policy # ADM1273. Based on his role as an IDM and the receipt of license income from the Agreement, this potential financial interest necessitates a personal Conflict of Interest Management Plan approved by the MD Anderson Conflict of Interest Committee.

Because MD Anderson is committed to the protection of human subjects and the effective management of its financial conflict of interest in relation to its research activities, MD Anderson has implemented an Institutional Conflict of Interest Management and Monitoring Plan (Plan) to manage and monitor the conflict of interest with respect to MD Anderson's conduct of the Studies. The Plan has been approved by the President of MD Anderson and the Executive Vice Chancellor for Health Affairs for The University of Texas System (EVC) and has been implemented by MD Anderson.

Prohibitive measures in the Plan include:

- Dr. Piwnica-Worms will not be involved in any negotiations with RV or its known affiliates with respect to sponsored research agreements, purchasing decisions or any other type of agreement.
- Dr. Piwnica-Worms will not be involved in the approval or execution of contracts or agreements involving RV on behalf of MD Anderson and the use of alternate arrangements for the processing of such agreements involving RV for final approval and execution.
- Dr. Piwnica-Worms will not be involved in any relevant discussions at RV and MD Anderson except as specifically invited by MD Anderson as a content expert.
- Dr. Piwnica-Worms will not supervise anyone participating in discussions involving any existing or proposed business relationships or research collaboration involving RV and MD Anderson.

The Plan requirements include:

- MD Anderson employees who have both a financial interest in RV and will be involved in the conduct of the Studies will have a personal conflict of interest management plan covering their involvement in the Studies.
- Disclosure of Dr. Piwnica-Worms' personal and institutional management plans (in general terms) to individuals directly supervised by or in the line of reporting to Dr. Piwnica-Worms.
- Altered reporting structure for individuals directly supervised by or in the line of reporting of David Piwnica-Worms who have a financial interest in or a financial relationship with RV and in those instances where such individuals' institutional responsibilities include negotiations or decisions involving RV.
- Prompt disclosure by Dr. Piwnica-Worms to the MD Anderson Conflict of Interest Committee with respect to existing business relationships or research collaborations involving RV and MD Anderson.
- Disclosure of MD Anderson's, Dr. Piwnica-Worms' (in general terms), and any investigator's financial conflict of interest to all Study participants, to all members of research teams who will work on the Studies, and in all publications and oral presentations concerning these Studies.
- Posting of this summary on MD Anderson's public website.
- Referral of any concerns/complaints related to MD Anderson's or Dr Piwnica-Worms' compliance with the Plan, or its financial conflict of interest, to The University of Texas System.

- Recusal of any MD Anderson Institutional Decision Maker who has a financial relationship with RV or its known affiliates from negotiations with respect to any agreements or purchasing decisions.
- For any human subjects research subject to this Plan, MD Anderson will disclose both the names of the significant creators of the licensed technology and the fact that they will collectively be entitled to 50% of the license income generated by the Agreements, pursuant to MD Anderson policy.
- For any Clinical Trials, no creator of the licensed technology may serve as a Principal Investigator or Co-Investigator, nor may they enroll patients on said Clinical Trials.
- Third party monitoring of the eligibility criteria and safety and efficacy data for any Clinical Trial.
- Oversight of Studies by an external Institutional Review Board (External IRB), including reporting to the External IRB by MD Anderson's Investigational New Drug (IND) Office when applicable.
- Engagement of a non-MD Anderson ethicist (External Ethicist) to address any questions or concerns that participants in the Studies may have pertaining to the MD Anderson's or Dr. Piwnica-Worms' financial interest and conflict of interest.
- Supply a copy of the Plan to the External IRB and External Ethicist.
- Review of safety and efficacy data of Studies that are clinical trials by an external and independent Data Safety Monitoring Board (External DSMB).
- Use of multi-institutional trials with a non-MD Anderson lead principal investigator for Studies that are Phase III or Phase II clinical trials aimed at gaining FDA approval under a new drug or biological license application.
- Monitoring activities related to the manufacture of Investigational Agents, if required for the Studies, by MD Anderson's IND Office.
- Reporting to the EVC by an External Contract Research Organization on Studies that are IND-enabling preclinical studies.
- Review and revision of the Plan as necessary with any amendments requiring EVC approval.
- Annual review of MD Anderson's compliance with the Plan by MD Anderson's Institutional Conflict of Interest Committee and MD Anderson Institutional Compliance, with a report of such review provided to The University of Texas System Ethics Officer.

Prepared November 7, 2024